

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	E04X01
Policy Title	Use of Plerixafor for Stem Cell Mobilisation (Update to include paediatrics)
Accountable Commissioner	Penelope Gray
Clinical Reference Group	Paediatric Cancer Services
Which stakeholders were contacted to be involved in policy development?	Paediatric Cancer Services CRG membership Paediatric Cancer Services CRG registered stakeholders Children's Cancer and Leukaemia Group (CCLG) ClicSargent Children with Cancer Teenage and Young People Cancer CRG Adult Cancer CRG
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable

FOR PUBLIC CONSULTATION ONLY

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None</p>
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Two responses were received in total; one from CRG-registered stakeholders and one from CRG members.</p> <p>Key response themes were as follows:</p> <p>(1) CRG member noted that the indication terminology could be misinterpreted. PWG maintained that terminology should be consistent with the one used in the evidence review</p> <p>(2) Stakeholder requested changes be made in the drug administration schedule of plerixafor. PWG maintained that the policy proposition should be in line with the EMA license</p> <p>(3) Stakeholder also identified other stakeholders which they suggested should be included in the consultation phase. PWG noted that these were already contacted as part of stakeholder testing.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. See Appendix for detailed stakeholder comments. No changes made to the evidence review or policy proposition.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders</p>